Early Experience of Treprostinil Dry-Powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Tertiary Referral Center

Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), yet data on screening in heterogenous ILD populations are limited. We evaluated whether routinely measured pulmonary function test (PFT) parameters identify individuals with intermediate-to-high echocardiographic risk of PH.

Chronic obstructive pulmonary disease (COPD) is frequently associated with pulmonary vascular disease (PVD) yet pulmonary vascular involvement remains underrecognized and incompletely phenotyped.

Pulmonary hypertension (PH) is a frequent complication of fibrotic interstitial lung diseases (ILDs), but its detection remains challenging due to overlapping clinical features. We aimed to evaluate the discriminatory power of physiological and exercise-based markers that differentiate right heart catheterization (RHC)—confirmed PH from low-probability ILD cases. 

Right heart catheterization (RHC) and echocardiography are integral in the assessment of pulmonary hypertension (PH) and cardiac function for lung transplant (LT) candidates. However, the impact of these metrics on post-LT outcomes remains unclear.